PT  - JOURNAL ARTICLE
AU  - TACHIKAWA, YUICHI
AU  - KAWAI, KAZUSHIGE
AU  - OZAKI, KOSUKE
AU  - NOZAWA, HIROAKI
AU  - SASAKI, KAZUHITO
AU  - MURONO, KOJI
AU  - EMOTO, SHIGENOBU
AU  - KISHIKAWA, JUNKO
AU  - YOKOYAMA, YUICHIRO
AU  - ABE, SHINYA
AU  - NAGAI, YUZO
AU  - ANZAI, HIROYUKI
AU  - SONODA, HIROFUMI
AU  - ISHIHARA, SOICHIRO
TI  - CD133(+)HIF-1α(−) Expression After Chemoradiotherapy Predicts Poor Prognosis in Rectal Cancer
AID  - 10.21873/anticanres.15684
DP  - 2022 Apr 01
TA  - Anticancer Research
PG  - 2033--2043
VI  - 42
IP  - 4
4099  - http://ar.iiarjournals.org/content/42/4/2033.short
4100  - http://ar.iiarjournals.org/content/42/4/2033.full
SO  - Anticancer Res2022 Apr 01; 42
AB  - Background/Aim: CD133 and hypoxia-inducible factor 1α (HIF-1α) have been reported to be affected by chemoradiotherapy (CRT), but the combinatorial assessment of these markers for prognosis after CRT has not been fully investigated. Therefore, we aimed to predict recurrence and prognosis in patients with rectal cancer by assessing changes in the expression of both CD133 and HIF-1α after CRT. Materials and Methods: CD133 and HIF-1α expression was evaluated by immunohistochemistry in surgical specimens from 243 patients with advanced low rectal cancer who received CRT followed by curative resection. Results: The positivity rate of CD133 expression showed increase with increased HIF-1α expression. The combination of these two markers showed that the CD133(+)HIF-1α(−) group exhibited a markedly shorter relapse-free survival (p=0.007), higher liver recurrence (p=0.004), and higher local recurrence (p=0.006). Conclusion: CD133(+)HIF-1α(−) expression after CRT is a promising marker to predict recurrence in rectal cancer.